筋萎縮性側索硬化症に関する治験推進のための医療DX・治験DX

抄録

The promotion of clinical trials for amyotrophic lateral sclerosis (ALS) can greatly benefit from medical and clinical trial digital transformation (DX) by reducing the burden on patients and their families. The role of Medical and Clinical Trial DX should be described from three perspectives : Academic Research Organizations (AROs), medical institutions and healthcare providers, and patients and their families. The utilization of digital technologies, such as telemedicine and decentralized clinical trials (DCT), contributes to enhancing trial efficiency and lowering barriers to trial participation for patients. However, addressing technical challenges and financial adjustments remains necessary. The implementation and improvement of medical and clinical trial DX are expected to create an environment where ALS patients can access more treatment opportunities.